Nippon Shinyaku Co.,Ltd. Logo

Nippon Shinyaku Co.,Ltd.

Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.

4516 | T

Overview

Corporate Details

ISIN(s):
JP3717600005
LEI:
Country:
Japan
Address:
京都市南区吉祥院西ノ庄門口町14番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nippon Shinyaku Co., Ltd. is a research and development-oriented company engaged in the manufacturing and commercialization of pharmaceuticals and functional foods. The company's core business is its Pharmaceuticals division, which develops and sells a range of prescribed drugs, including specialty and generic medications, with a focus on therapeutic areas such as urinary, neurological, respiratory, and circulatory disorders. The Functional Foods division leverages the company's pharmaceutical expertise to produce and market high-quality health food products. Nippon Shinyaku is committed to supplying original, high-quality products to contribute to the healthcare sector and improve wellbeing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 06:45
Registration Form
確認書
Japanese 8.7 KB
2025-11-14 06:43
Interim Report
半期報告書-第163期(2025/04/01-2026/03/31)
Japanese 233.6 KB
2025-07-04 06:16
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2025-06-24 06:23
Registration Form
確認書
Japanese 8.6 KB
2025-06-24 06:22
Governance Information
内部統制報告書-第162期(2024/04/01-2025/03/31)
Japanese 26.1 KB
2025-06-24 06:18
Annual Report
有価証券報告書-第162期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 02:12
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-11-14 02:11
Interim Report
半期報告書-第162期(2024/04/01-2025/03/31)
Japanese 233.5 KB
2024-07-01 04:04
Post-Annual General Meeting Information
臨時報告書
Japanese 29.3 KB
2024-06-28 04:07
Governance Information
内部統制報告書-第161期(2023/04/01-2024/03/31)
Japanese 23.3 KB
2024-06-28 04:01
Registration Form
確認書
Japanese 8.6 KB
2024-06-28 03:58
Annual Report
有価証券報告書-第161期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2024-02-14 02:06
Report Publication Announcement
確認書
Japanese 8.6 KB
2024-02-14 02:05
Quarterly Report
四半期報告書-第161期第3四半期(2023/10/01-2023/12/31)
Japanese 244.8 KB
2023-11-14 01:59
Report Publication Announcement
確認書
Japanese 8.6 KB

Automate Your Workflow. Get a real-time feed of all Nippon Shinyaku Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nippon Shinyaku Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nippon Shinyaku Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.